About: Use of MAR Elements to Increase the Production of Recombinant Proteins

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of MAR Elements to Increase the Production of Recombinant Proteins Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Use of MAR Elements to Increase the Production of Recombinant Proteins
Creator	Al, M Mermod, Nicolas Arope, S Arope, Salina Girod, P.-A Girod, Pierre-Alain Gorman, C Gorman, Cori Grandjean, M Grandjean, Mélanie Mermod, N
topic	covid:e73dea1124bab4bff672d6ceaf2709b5039761ae#this
source	PMC
abstract	The biopharmaceutical industry continues to face the challenge of producing large amount of recombinant proteins for use as therapeutics, and eighty percent of protein therapeutics in clinical development are produced in mammalian cell systems. Approaches to increase production addressing growth conditions, such as the improvement of media composition and process control, or transcription of the recombinant gene via the use of strong promoters/enhancers and amplification of gene copy number, have increased the yields obtained from mammalian cells considerably over the past decades. However these processes remain laborious, and extensive screening of clones is often required, as stable cell line and/or protein production is not always obtained. Unstable or variable expression is linked to the location of transgene integration site, the regulation of gene expression, the silencing of genes, and the loss of gene copies. Genetic elements that may remodel chromatin to maintain the transgene in an active configuration are now being employed increasingly to improve protein production using mammalian cells. Here we will review how one type of such elements, the MARs, may increase transgene integration into the cell genome and decrease silencing effects to reduce expression variability. We also illustrate how inclusion of these elements in expression vectors leads to increased specific productivities ranging from 20 to 100 picograms per cell and per day (p/c/d), resulting in protein titers above 5 g/l.
has issue date	2009-07-19(xsd:dateTime)
bibo:doi	10.1007/978-90-481-2245-5_1
has license	no-cc
sha1sum (hex)	e73dea1124bab4bff672d6ceaf2709b5039761ae
schema:url	https://doi.org/10.1007/978-90-481-2245-5_1
resource representing a document's title	Use of MAR Elements to Increase the Production of Recombinant Proteins
has PubMed Central identifier	PMC7121902
schema:publication	Cell Line Development
resource representing a document's body	covid:e73dea1124bab4bff672d6ceaf2709b5039761ae#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/e73dea1124bab4bff672d6ceaf2709b5039761ae
is schema:about of	named entity 'cell' named entity 'genes' named entity 'gene' named entity 'Genetic' named entity 'decades' named entity 'SILENCING' named entity 'EXPRESSION' named entity 'SITE' named entity 'INDUSTRY' named entity 'CELLS' named entity 'THERAPEUTICS' named entity 'COPIES' named entity 'CELL SYSTEMS' named entity 'RECOMBINANT PROTEINS' named entity 'extensive' named entity 'yields' named entity 'specific' named entity 'Here' named entity 'ranging' named entity 'face' named entity 'RNAi' named entity 'PCR' named entity 'transgene' named entity 'DNA replication' named entity 'myeloma' named entity 'mRNA' named entity 'enhancer' named entity 'kidney' named entity 'SATB1' named entity 'IL-2' named entity 'lysozyme' named entity 'heterochromatin' named entity 'immunoglobulin' named entity 'chicken' named entity 'epigenetic' named entity 'interferon' named entity 'SATB1' named entity 'nuclear structure' named entity 'MAR' named entity 'ICR' named entity 'HMG' named entity 'copy number' named entity 'CHO' named entity 'gene' named entity 'MAR' named entity 'epigenetic modification' named entity 'HMGA' named entity 'chromatin' named entity 'illustrate' named entity 'protein' named entity 'elements' named entity 'Production' named entity 'Use' named entity 'protein' named entity 'protein production' named entity 'enhancers' named entity 'cell genome' named entity 'mammalian cell' named entity 'MARs' named entity 'gene' named entity 'Production of Recombinant Proteins' named entity 'chromatin' named entity 'random distribution' named entity 'minor groove' named entity 'lysozyme' named entity 'MAR' named entity 'nucleus' named entity 'gene amplification' named entity 'gene copy number' named entity 'titer' named entity 'interferon'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software